Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis.
OBJECTIVE
To report the efficacy of intravitreal bevacizumab injection in treatment of macular edema in a case of optic disc vasculitis.


METHODS
Retrospective case review.


METHODS
A patient diagnosed with macular edema due to optic disc vasculitis was treated with intravitreal bevacizumab injection.


RESULTS
One week after injection, fundus appearance dramatically improved and macular edema regressed. The patient was followed up for 1 year after injection and there was no recurrence of macular edema.


CONCLUSIONS
This case suggests that intravitreal bevacizumab treatment might be effective in the management of macular edema in patients with optic disc vasculitis.
Erdurman
F Cüneyt
FC
Department of Ophthalmology, Gülhane Military Medical Academy and Medical School, Etlik, Ankara, Turkey. erdurman@yahoo.com
Durukan
A Hakan
AH
Mumcuoğlu
Tarkan
T
Hürmeriç
Volkan
V
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009898:Optic Disk / Q000098:blood supply*; D031300:Retinal Vasculitis / Q000150:complications*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab